ESMO HIGHLIGHTS 2024 – MELANOMA ROUNDTABLE DISCUSSION: PD-1 Updates

00:10

LBA45 Early switch from targeted to immunotherapy in advanced BRAFV600-positive melanoma: Long-term OS and final PFS results of the randomized phase 2 ImmunoCobiVem trial

02:16

LBA46 Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab

Icon Chair Speaker

Chair

Dr. Teresa Petrella

Icon Chair Speaker

Panelists

Dr. Marcus Butler
Dr. Caroline Robert